The article is for discussion and illustrative purposes only and not an investment recommendation or signal for any company, sector, or industry. Investors are solely responsible for their own investment decisions. The article is not a paid endorsement. No financial compensation was received from any company mentioned in this article. The information and materials are provided as a general source of information. While every measure has been taken to ensure the accuracy of the material, we do not guarantee the accuracy or completeness of the material. It is not intended as investment, financial, legal, accounting, tax or other advice. The dynamics are changing frequently. Any information or materials which are provided or maintained by a third party such as linked sites and references which may be accessed but are provided “as is”. We will not be responsible in any manner for direct, indirect or special damages, howsoever caused, arising out of the use of this information.
Lexaria Bioscience (CSE: LXX; OTCQX: LXRP)
- Lexaria’s DehydraTECH™ technology is designed to deliver cannabinoids in oral product formats with significantly enhanced palatability, speed of effectiveness and potency as a viable and healthier alternative to conventional inhalational (i.e. smoking or vaping) administration practices
- Lexaria has three distinct consumer product brands: ViPovaTM (patented process to create a more comforting and effective process of delivering active hemp oil ingredients through familiar products), Lexaria Energy Foods (with full spectrum hemp oil constituents with patent pending technology proven to provide up to 499% better absorption of these ingredients into human intestinal cells) and TurboCBD™ (with no hemp oil aftertaste)
As consumers become more aware of the benefits of hemp-based products, demand should follow suit. Canadian companies have long been recognized as leaders in the production of hemp and hemp food products. Historically, Canada has had a head start on its US neighbours, but as laws become laxed and regulations are set to change, this could change fast. Nonetheless, there is a sizable opportunity in this space, and the plethora of publicly-traded Canadian companies outlined above are case in point. Whether that changes with the new regulations
coming into place in the United States soon,
remains to be seen. Removing it from Health
Canada’s control could provide a level playing
field here, but regardless, the potential for
growth in this high-margin sector is huge.
Spiro Sertsis, CPA, CMA
@SpiroSertsis
159